AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below without prejudice or disclaimer. This claim listing replaces all prior versions and listings.

1-38. Cancelled.

39. (New) A pharmaceutical composition comprising a plurality of composite subunits, wherein each composite subunit comprises a sequestering subunit comprising an opioid antagonist and a material substantially preventing the release of the opioid antagonist from the sequestering subunit, wherein the sequestering subunit is coated with an opioid agonist in releasable form.

40. (New) The pharmaceutical composition of claim 39 wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazocine, and levallorphan.

41. (New) The pharmaceutical composition of claim 40 wherein the opioid antagonist is naltrexone.

42. (New) The pharmaceutical composition of claim 40 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

43. (New) The pharmaceutical composition of claim 42 wherein the opioid agonist is morphine.

44. (New) The pharmaceutical composition of claim 39 wherein the opioid antagonist is naltrexone and the opioid agonist is morphine.

45. (New) The pharmaceutical composition of claim 39 wherein the material comprises a pharmaceutically acceptable hydrophobic material.

46. (New) The pharmaceutical composition of claim 45 wherein the pharmaceutically acceptable hydrophobic material is a polymer insoluble in the gastrointestinal tract.

47. (New) The pharmaceutical composition of claim 46 wherein the pharmaceutically acceptable hydrophobic material is an acrylic resin comprising a copolymer synthesized from ethyl acrylate, methyl methacrylate and trimethylammoniummethyl methacrylate chloride.

48. (New) The pharmaceutical composition of claim 39, 44 or 45 wherein the material comprises a surfactant.

49. (New) The pharmaceutical composition of claim 48 wherein the surfactant is sodium lauryl sulfate.

50. (New) A pharmaceutical composition comprising a first layer comprising a sequestering subunit comprising an opioid antagonist and a material substantially preventing the release of the opioid antagonist from the sequestering subunit and a second layer comprising an opioid agonist in releasable form, wherein the first layer is coated with the second layer.

51. (New) The pharmaceutical composition of claim 50 wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazocine, and levallorphan.

52. (New) The pharmaceutical composition of claim 51 wherein the opioid antagonist is naltrexone.

53. (New) The pharmaceutical composition of claim 50 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

54. (New) The pharmaceutical composition of claim 53 wherein the opioid agonist is morphine.

55. (New) The pharmaceutical composition of claim 50 wherein the opioid antagonist is naltrexone and the opioid agonist is morphine.

56. (New) The pharmaceutical composition of claim 50 wherein the material comprises a pharmaceutically acceptable hydrophobic material.

57. (New) The pharmaceutical composition of claim 56 wherein the pharmaceutically acceptable hydrophobic material is a polymer insoluble in the gastrointestinal tract.

58. (New) The pharmaceutical composition of claim 57 wherein the pharmaceutically acceptable hydrophobic material is an acrylic resin comprising a copolymer synthesized from ethyl acrylate, methyl methacrylate and trimethylammoniummethyl methacrylate chloride.

59. (New) The pharmaceutical composition of claim 50, 55 or 56 wherein the material comprises a surfactant.

60. (New) The pharmaceutical composition of claim 59 wherein the surfactant is sodium lauryl sulfate.

61. (New) A pharmaceutical composition comprising a sequestering subunit comprising an opioid antagonist and a blocking agent, wherein an opioid agonist composition overcoats the sequestering subunit.

62. (New) The pharmaceutical composition of claim 61 wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazocine, and levallorphan.

63. (New) The pharmaceutical composition of claim 62 wherein the opioid antagonist is naltrexone.

64. (New) The pharmaceutical composition of claim 61 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

65. (New) The pharmaceutical composition of claim 64 wherein the opioid agonist is morphine.

66. (New) The pharmaceutical composition of claim 61 wherein the opioid antagonist is naltrexone and the opioid agonist is morphine.

67. (New) The pharmaceutical composition of claim 61 wherein the blocking agent comprises a pharmaceutically acceptable hydrophobic material.

68. (New) The pharmaceutical composition of claim 67 wherein the pharmaceutically acceptable hydrophobic material is a polymer insoluble in the gastrointestinal tract.

69. (New) The pharmaceutical composition of claim 68 wherein the pharmaceutically acceptable hydrophobic material is an acrylic resin comprising a copolymer synthesized from ethyl acrylate, methyl methacrylate and trimethylammoniummethyl methacrylate chloride.

70. (New) The pharmaceutical composition of claim 61, 66 or 67 wherein the blocking agent comprises a surfactant.

71. (New) The pharmaceutical composition of claim 70 wherein the surfactant is sodium lauryl sulfate.

72. (New) A sequestering subunit comprising an aversive agent and a blocking agent, wherein the aversive agent is an opioid antagonist and the blocking agent comprises a material substantially impermeable to the aversive agent and a surfactant.

73. (New) The sequestering subunit of claim 72 wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazocine, and levallorphan.

74. (New) The sequestering subunit of claim 73 wherein the opioid antagonist is naltrexone.

75. (New) The sequestering subunit of claim 72 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

76. (New) The sequestering subunit of claim 75 wherein the opioid agonist is morphine.

77. (New) The sequestering subunit of claim 72 wherein the opioid antagonist is naltrexone and the opioid agonist is morphine.

78. (New) The sequestering subunit of claim 72 wherein the material comprises a pharmaceutically acceptable hydrophobic material.

79. (New) The sequestering subunit of claim 78 wherein the pharmaceutically acceptable hydrophobic material is a polymer insoluble in the gastrointestinal tract.

80. (New) The sequestering subunit of claim 79 wherein the pharmaceutically acceptable hydrophobic material is an acrylic resin comprising a copolymer synthesized from ethyl acrylate, methyl methacrylate and trimethylammoniummethyl methacrylate chloride.

81. (New) The sequestering subunit of claim 72, 77 or 78 wherein the surfactant is sodium lauryl sulfate.

82. (New) The pharmaceutical composition of any one of claims 39 or 50 wherein the material prevents at least about 90% of the aversive agent from being released after approximately 48 hours as determined by dissolution testing conducted according to USP26 Chapter <711>.

83. (New) The pharmaceutical composition of any one of claims 39 or 50 wherein the material prevents at least about 95% of the aversive agent from being released after approximately 24 hours as determined by dissolution testing conducted according to USP26 Chapter <711>.

84. (New) The pharmaceutical composition of any one of claims 39 or 50 wherein the material prevents at least about 99% of the aversive agent from being released after

approximately 12 hours as determined by dissolution testing conducted according to USP26 Chapter <711>.

85. (New) The pharmaceutical composition of any one of claims 61 or 72 wherein the blocking agent prevents at least about 90% of the aversive agent from being released after approximately 48 hours as determined by dissolution testing conducted according to USP26 Chapter <711>.

86. (New) The pharmaceutical composition of any one of claims 61 or 72 wherein the blocking agent prevents at least about 95% of the aversive agent from being released after approximately 24 hours as determined by dissolution testing conducted according to USP26 Chapter <711>.

87. (New) The pharmaceutical composition of any one of claims 61 or 72 wherein the blocking agent prevents at least about 99% of the aversive agent from being released after approximately 12 hours as determined by dissolution testing conducted according to USP26 Chapter <711>.